Bone Therapeutics SA, of Gosselies, Belgium, licensed the Japanese rights to its autologous bone cell therapy product, Preob, for the treatment of osteonecrosis of the hip with the potential for other orthopedic and bone applications to Asahi Kasei Corp., of Tokyo.